Fermenta wins FSSAI nod for plant-based Vitamin D3
VITADEE Green gets regulatory clearance, opening India's vegetarian supplement market for a micro-cap with trailing revenue decline.
— 3 earlier stories on Fermenta Biotech Ltd. →What's new
- FSSAI approved Fermenta's plant-sourced Vitamin D3, VITADEE Green.
- Product is developed and manufactured in India; commercial launch planned in FY27.
- Approval adds to existing D3 portfolio and targets clean-label demand.
Why this matters
A micro-cap with trailing revenue down 13% just unlocked a new growth lane. Plant-based D3 is a fast-growing niche, but the financial impact is unquantified. The approval itself is the milestone, not the revenue it will generate.
What we're watching
- Speed and scale of the VITADEE Green commercial rollout.
- Any revenue mention in FY27 quarterly results.
- Competitor moves in the plant-based D3 space.
The full read
Fermenta Biotech has secured FSSAI approval for VITADEE Green, a plant-sourced Vitamin D3 developed and manufactured in India. For a micro-cap with a market cap of ₹1,072 crore and trailing revenue down 13%, regulatory clearances for differentiated products are rare. This one resolves regulatory uncertainty and enables commercial launch this fiscal year, tapping into the vegetarian supplement market. No financial estimates are attached. The move strengthens Fermenta's existing Vitamin D3 portfolio and aligns with clean-label trends. Now the test is execution.
Questions answered
- What exactly did Fermenta Biotech receive approval for?
- FSSAI approved its plant-based Vitamin D3 product branded VITADEE Green, allowing the company to market it in India's food and supplements market.
- How does this product differ from existing Vitamin D3 supplements?
- VITADEE Green is sourced from plants, addressing the growing demand for vegetarian and clean-label supplements. Most Vitamin D3 is animal-derived (lanolin).
- When will VITADEE Green be commercially available?
- Fermenta plans to launch commercially in the current financial year (FY27), following the regulatory clearance.
- How significant is this approval for a company of Fermenta's size?
- With a market cap of ₹1,072 crore and trailing revenue down 13%, a differentiated product approval can open a new revenue stream, though the financial contribution is not yet disclosed.
Story so far
All notes on FERMENTA →- 3 Jul 2026 · 7:17 PM IST Fermenta wins FSSAI nod for plant-based Vitamin D3
- 38d ago Fermenta's underlying business grew 26% even as PAT fell 8% on a high base
- 38d ago Fermenta Biotech eyes NSE listing and a dilutive subsidiary deal
- 38d ago Fermenta's profit falls 5% despite revenue growth, cushioned by a one-off